127 related articles for article (PubMed ID: 35483431)
1. Acceptability of the contraceptive Sayana® Press when injected every four months: Results from a twelve-month trial in Brazil, Chile and the Dominican Republic.
Burke HM; Packer C; Fuchs R; Brache V; Bahamondes L; Salinas A; Veiga N; Miller A; Deese J
Contraception; 2022 Sep; 113():95-100. PubMed ID: 35483431
[TBL] [Abstract][Full Text] [Related]
2. Contraceptive effectiveness, pharmacokinetics, and safety of Sayana® Press when injected every four months: a multicenter phase 3 trial.
Deese J; Brache V; Bahamondes L; Salinas A; Jorge A; Veiga N; Fuchs R; Miller A; Taylor D; Halpern V; Dorflinger L
EClinicalMedicine; 2022 Feb; 44():101273. PubMed ID: 35128365
[TBL] [Abstract][Full Text] [Related]
3. Acceptability of the community-level provision of Sayana® Press by medical and nursing students in Kinshasa, Democratic Republic of the Congo.
Bertrand JT; Makani PB; Hernandez J; Akilimali P; Mukengeshayi B; Babazadeh S; Binanga A
Contraception; 2017 Sep; 96(3):211-215. PubMed ID: 28647500
[TBL] [Abstract][Full Text] [Related]
4. A prospective cohort study to assess the acceptability of Sayana Press among 18-49-year-old women in Nepal.
Sherpa LY; Tinkari BS; Gentle P; Sah RK; Shrestha A; Sahani SK; Aryal K; Ghimire J; Karki DK
Contraception; 2021 Dec; 104(6):623-627. PubMed ID: 34280441
[TBL] [Abstract][Full Text] [Related]
5. Introductory study of the once-a-month, injectable contraceptive Cyclofem in Brazil, Chile, Colombia, and Peru.
Hall P; Bahamondes L; Diaz J; Petta C
Contraception; 1997 Dec; 56(6):353-9. PubMed ID: 9494768
[TBL] [Abstract][Full Text] [Related]
6. Young Women's Experiences With Subcutaneous Depot Medroxyprogesterone Acetate: A Secondary Analysis of a One-Year Randomized Trial in Malawi.
Burke HM; Chen M; Packer C; Fuchs R; Ngwira B
J Adolesc Health; 2020 Nov; 67(5):700-707. PubMed ID: 32389457
[TBL] [Abstract][Full Text] [Related]
7. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.
Polis CB; Nakigozi GF; Nakawooya H; Mondo G; Makumbi F; Gray RH;
Contraception; 2014 May; 89(5):385-95. PubMed ID: 24332432
[TBL] [Abstract][Full Text] [Related]
8. A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection.
Cover J; Namagembe A; Tumusiime J; Lim J; Drake JK; Mbonye AK
Contraception; 2017 Mar; 95(3):306-311. PubMed ID: 27789309
[TBL] [Abstract][Full Text] [Related]
9. Home-based administration of Sayana® Press: review and assessment of needs in low-resource settings.
Keith B; Wood S; Tifft S; Hutchings J
Contraception; 2014 May; 89(5):344-51. PubMed ID: 24813924
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study.
Cover J; Ba M; Lim J; Drake JK; Daff BM
Contraception; 2017 Sep; 96(3):203-210. PubMed ID: 28673645
[TBL] [Abstract][Full Text] [Related]
12. Pilot Research as Advocacy: The Case of Sayana Press in Kinshasa, Democratic Republic of the Congo.
Binanga A; Bertrand JT
Glob Health Sci Pract; 2016 Dec; 4(4):542-551. PubMed ID: 27979874
[TBL] [Abstract][Full Text] [Related]
13. Return to ovulation after Sayana Press is injected every 4 months for one year: Empirical and pharmacokinetic/pharmacodynamic modeling results.
Taylor DJ; Deese J; Bahamondes L; Brache V; Veiga N; Fuchs R; Halpern V; Dorflinger LJ
Contracept X; 2022; 4():100080. PubMed ID: 35965654
[TBL] [Abstract][Full Text] [Related]
14. Perceptions of home and self-injection of Sayana® Press in Ethiopia: a qualitative study.
Keith B; Wood S; Chapman C; Alemu E
Contraception; 2014 May; 89(5):379-84. PubMed ID: 24529492
[TBL] [Abstract][Full Text] [Related]
15. Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal.
Burke HM; Mueller MP; Perry B; Packer C; Bufumbo L; Mbengue D; Mall I; Daff BM; Mbonye AK
Contraception; 2014 May; 89(5):361-7. PubMed ID: 24631328
[TBL] [Abstract][Full Text] [Related]
16. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
[TBL] [Abstract][Full Text] [Related]
17. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
[TBL] [Abstract][Full Text] [Related]
18. Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda.
Cover J; Namagembe A; Tumusiime J; Nsangi D; Lim J; Nakiganda-Busiku D
Contraception; 2018 Nov; 98(5):383-388. PubMed ID: 29654751
[TBL] [Abstract][Full Text] [Related]
19. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
Swenson I; Khan AR; Jahan FA
Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
[TBL] [Abstract][Full Text] [Related]
20. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
Polaneczky M; Guarnaccia M; Alon J; Wiley J
Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
